` RDHL (Redhill Biopharma Ltd) vs S&P 500 Comparison - Alpha Spread

RDHL
vs
S&P 500

Over the past 12 months, RDHL has underperformed S&P 500, delivering a return of -82% compared to the S&P 500's +15% growth.

Stocks Performance
RDHL vs S&P 500

Loading
RDHL
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
RDHL vs S&P 500

Performance Gap Between RDHL and GSPC
HIDDEN
Show

Performance By Year
RDHL vs S&P 500

Loading
RDHL
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Redhill Biopharma Ltd vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Redhill Biopharma Ltd
Glance View

Market Cap
3.8m USD
Industry
Pharmaceuticals

RedHill Biopharma Ltd. is a biopharmaceutical company focusing gastrointestinal and infectious diseases. The firm promotes three gastrointestinal drugs in the US: Movantik, Talicia and Aemcolo. Key programs in it pipeline of late-stage clinical assets include: opaganib (Yeliva) and RHB-107 for multiple indications including COVID-19, RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease and RHB-104 for Crohn's disease.

RDHL Intrinsic Value
HIDDEN
Show
Back to Top